143 related articles for article (PubMed ID: 23825903)
1. Impact of comorbidity in elderly prostate cancer patients treated with brachytherapy.
Chiumento C; Fiorentino A; Cozzolino M; Caivano R; Clemente S; Pedicini P; Fusco V
Chin J Cancer Res; 2013 Jun; 25(3):274-80. PubMed ID: 23825903
[TBL] [Abstract][Full Text] [Related]
2. Comparison of common terminology criteria for adverse events v3.0 and radiation therapy oncology group toxicity score system after high-dose-rate interstitial brachytherapy as monotherapy for prostate cancer.
Yoshida K; Yamazaki H; Nakamara S; Masui K; Kotsuma T; Akiyama H; Tanaka E; Yoshioka Y
Anticancer Res; 2014 Apr; 34(4):2015-8. PubMed ID: 24692740
[TBL] [Abstract][Full Text] [Related]
3. Long-Term Efficacy and Toxicity of Low-Dose-Rate ¹²⁵I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer.
Kittel JA; Reddy CA; Smith KL; Stephans KL; Tendulkar RD; Ulchaker J; Angermeier K; Campbell S; Stephenson A; Klein EA; Wilkinson DA; Ciezki JP
Int J Radiat Oncol Biol Phys; 2015 Jul; 92(4):884-93. PubMed ID: 25962627
[TBL] [Abstract][Full Text] [Related]
4. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
Spratt DE; Zumsteg ZS; Ghadjar P; Kollmeier MA; Pei X; Cohen G; Polkinghorn W; Yamada Y; Zelefsky MJ
BJU Int; 2014 Sep; 114(3):360-7. PubMed ID: 24447404
[TBL] [Abstract][Full Text] [Related]
5. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
6. Low-dose rate brachytherapy of the prostate in elderly patients.
Chiumento C; Fiorentino A; Caivano R; Clemente S; Fusco V
Radiol Med; 2013 Dec; 118(8):1412-21. PubMed ID: 22986692
[TBL] [Abstract][Full Text] [Related]
7. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ
BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568
[TBL] [Abstract][Full Text] [Related]
8. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy for elder patients aged ≥80 with clinically localized prostate cancer - Brachytherapy enhanced late GU toxicity especially in elderly.
Yamazaki H; Masui K; Suzuki G; Shimizu D; Aibe N; Yamada K; Fujihara A; Shiraishi T; Okihara K; Ukimura O; Yoshida K; Nakamura S; Okabe H
Clin Transl Radiat Oncol; 2020 Nov; 25():67-74. PubMed ID: 33102817
[TBL] [Abstract][Full Text] [Related]
10. Influence of the technique and comorbidities in hypofractionated radiotherapy for prostate cancer.
Correa R; Navarro I; Lobato M; Otero A; Jerez I; Rico JM; Zapata I; Lupiañez Y; Medina JA; Olmos D; Gómez-Millán J
Clin Transl Oncol; 2020 Mar; 22(3):311-318. PubMed ID: 31721011
[TBL] [Abstract][Full Text] [Related]
11. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
12. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
13. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study.
Büchser D; Casquero F; Espinosa JM; Perez F; Minguez P; Martinez-Indart L; Suarez F; Gonzalez A; Cacicedo J; San Miguel I; Maleta A; Gomez-Caamaño A; Bilbao P; Gomez-Iturriaga A
Radiother Oncol; 2019 Jun; 135():13-18. PubMed ID: 31015158
[TBL] [Abstract][Full Text] [Related]
14. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
[TBL] [Abstract][Full Text] [Related]
15. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer.
Koontz BF; Chino J; Lee WR; Hahn CA; Buckley N; Huang S; Kim J; Reagan R; Joyner R; Anscher MS
Brachytherapy; 2009; 8(2):191-196. PubMed ID: 19433320
[TBL] [Abstract][Full Text] [Related]
16. Charlson Comorbidity score influence on prostate cancer survival and radiation-related toxicity.
Ghanem AI; Khalil RM; Khedr GA; Tang A; Elsaid AA; Chetty IJ; Movsas B; Elshaikh MA
Can J Urol; 2020 Apr; 27(2):10154-10161. PubMed ID: 32333734
[TBL] [Abstract][Full Text] [Related]
17. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy.
Ghadjar P; Keller T; Rentsch CA; Isaak B; Behrensmeier F; Stroux A; Thalmann GN; Aebersold DM
Brachytherapy; 2009; 8(1):45-51. PubMed ID: 19038584
[TBL] [Abstract][Full Text] [Related]
18. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant.
Eade TN; Horwitz EM; Ruth K; Buyyounouski MK; D'Ambrosio DJ; Feigenberg SJ; Chen DY; Pollack A
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):338-45. PubMed ID: 18207665
[TBL] [Abstract][Full Text] [Related]
19. Urethra-sparing, intraoperative, real-time planned, permanent-seed prostate brachytherapy: toxicity analysis.
Zilli T; Taussky D; Donath D; Le HP; Larouche RX; Béliveau-Nadeau D; Hervieux Y; Delouya G
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e377-83. PubMed ID: 21514068
[TBL] [Abstract][Full Text] [Related]
20. Urethral toxicity vs. cancer control--lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer.
Ghadjar P; Rentsch CA; Isaak B; Behrensmeier F; Thalmann GN; Aebersold DM
Brachytherapy; 2011; 10(4):286-94. PubMed ID: 21030318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
